All posts in 'CAIA study'

ArthritoMab™ Case study

Posted on March 7th, 2011 · Posted in CAIA study

25 preclinical studies, 18 months, 1 out licensed compound With the number of blockbuster drugs approaching patent expiration and pharma companies struggling to maintain pipeline and portfolios with in-house programs, companies are increasingly turning to licensing, aquisitions and partnerships. Early-stage licensing deals tend to carry more risk for pharma companies..
Read more

Using the CAIA model as an alternative to the K/BxN model

Posted on January 10th, 2010 · Posted in CAIA study, K/BxN

K/BxN mice spontaneously develop a severe, chronic, progressive inflammatory arthritis at about 27 days of age. They develop auto-antibodies recognizing glucose-6-phosphate isomerase. Serum from these animals when transferred to recipient animals induce arthritis. The mechanism of action involves complement, mast cells, neutrophils and inflammatory mediators. This model is widely used for..
Read more